Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacological frontiers in the treatment of AIDS dementia
Autore:
McGuire, D; Marder, K;
Indirizzi:
Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA Univ Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA Columbia Presbyterian Med Ctr, New York, NY 10032 USA Columbia Presbyterian Med Ctr New York NY USA 10032 ew York, NY 10032 USA
Titolo Testata:
JOURNAL OF PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 14, anno: 2000,
pagine: 251 - 257
SICI:
0269-8811(200009)14:3<251:PFITTO>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; PLATELET-ACTIVATING-FACTOR; PROGRESSIVE ENCEPHALOPATHY; NONDEMENTED PATIENTS; HIV-1 ENCEPHALITIS; BRAINS; NEUROPATHOGENESIS; INFECTION; COMPLEX; RNA;
Keywords:
AIDS clinical trials; AIDS dementia complex; drug therapy; HIV encephalitis; neuroprotective agents;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: McGuire, D 643 Bair Isl Rd,Suite 210, Redwood City, CA USA 643 Bair Isl Rd,Suite 210 Redwood City CA USA od City, CA USA
Citazione:
D. McGuire e K. Marder, "Pharmacological frontiers in the treatment of AIDS dementia", J PSYCHOPH, 14(3), 2000, pp. 251-257

Abstract

Even in the era of highly active antiretroviral therapy, AIDS dementia remains an important and devastating complication of human immunodeficiency virus (HIV-1) infection. Based on the 1997 AIDS case rate of 56 per 100 000 population in the USA, a reasonable estimated incidence of AIDS dementia is 3-8 per 100 000, similar to that of multiple sclerosis. The pharmacology ofAIDS dementia has been dominated by antiretroviral therapies, the best studied of which is azidothymidine. New and specific therapies are needed to treat and prevent brain injury in the setting of HIV infection. Rational therapy has been limited by the absence of large, adequate and well-controlledclinical trials using neuroprotective agents or those with disease-modifying potential, as well as by an incomplete understanding of the pathophysiology of AIDS dementia. In this review, a summary of evidence-based hypotheses of HIV-associated brain injury is followed by information on current nonantiretroviral therapeutic trials and their scientific rationale.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 10:19:13